RxDoctor Payments Data

Ajay Manchandia, MD

Pediatric Ophthalmology and Strabismus Specialist · Orange, CANPI 1720243082

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.9% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Amgen at 28.2% of the total.

$843in general payments, 2019–2025

Across 29 payments — averaging $29.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$238
  • Eyevance Pharmaceuticals LLC$186
  • Sun Pharmaceutical Industries Inc.$130
  • Novartis$52
  • AbbVie$49
  • Alcon$37
  • plus $152 from 7 others

What the payments were for

  • Food & beverage$76791%
  • Education$779%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$843 in reported general payments places this provider in the 60th percentile of 28 pediatric ophthalmology and strabismus specialist providers in California.

See all pediatric ophthalmology and strabismus specialist providers in California

Medicare billing

Part B allowed, 2024
$8,073
Medicare patients
44
Services billed
64

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cyclosporine16$9,221
LumiganBimatoprost19$8,493
Latanoprost234$3,703
VyzultaLatanoprostene Bunod14$3,527
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat54$2,004
Timolol Maleate52$1,983
Brimonidine Tartrate33$738
ErythromycinErythromycin Base23$294
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha16$243
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol11$180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$49$8,49319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 28 pediatric ophthalmology and strabismus specialist providers in California.

Other pediatric ophthalmology and strabismus specialist in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →